Retatrutide Phase 2 Trial in MASLD — Liver Fat Reduction with Triple Agonist Therapy — VialBase Research

Summary

This sub-study of the retatrutide phase 2 obesity trial specifically evaluated the effect on hepatic steatosis (metabolic dysfunction-associated steatotic liver disease, MASLD) using MRI-derived proton density fat fraction (MRI-PDFF). Results demonstrated dramatic liver fat reduction, with many patients achieving complete normalization.

Key Findings

• Liver fat reduction of >80% from baseline at the 12mg dose at 48 weeks
• Majority of patients on higher doses achieved normal liver fat (<5% MRI-PDFF)
• Dose-dependent liver fat reduction across all dose levels
• Glucagon receptor agonism may uniquely contribute to hepatic fat mobilization
• Results exceed liver fat reductions seen with GLP-1 RAs or GIP/GLP-1 RAs
• Potential implications for MASH (metabolic dysfunction-associated steatohepatitis) treatment

Methodology

Pre-specified sub-study of the phase 2 obesity trial. 98 participants with MASLD (liver fat ≥10% by MRI-PDFF at baseline) assessed at multiple time points. Liver fat quantified by MRI-PDFF, a validated non-invasive measure. Treatment arms matched parent study.

Limitations

• Sub-study with smaller sample size (n=98)
• MRI-PDFF measures fat content, not fibrosis or inflammation (MASH)
• Cannot disentangle liver-specific effects from weight-loss-mediated effects
• No liver biopsy data (gold standard for MASH assessment)
• Phase 2 data — needs phase 3 confirmation

Relevance to Content

Opens a compelling content angle: retatrutide for liver health, not just weight loss. MASLD/MASH is a massive underdiagnosed condition. The glucagon component differentiates retatrutide from semaglutide/tirzepatide for liver fat. Relevant for content targeting metabolic health beyond the scale.

See Also

• Parent compound: Retatrutide
• Semaglutide
• Tirzepatide